Vaxart Inc. is a biotechnology company specializing in the development of oral recombinant vaccines. Its primary function is to create vaccine candidates that can be administered in tablet form, offering a painless and potentially more accessible alternative to traditional injectable vaccines. This innovation is particularly significant in addressing infectious diseases, where swift and efficient immunization can have substantial public health benefits. Vaxart operates at the intersection of medicine and technology, focusing on a variety of viral pathogens with an emphasis on influenza, norovirus, and coronaviruses. The company's oral vaccine platform not only has the potential to simplify distribution logistics but also aims to increase global vaccination rates by leveraging ease of administration. Founded in 2004 and headquartered in South San Francisco, California, Vaxart's role in the market is underscored by its innovative approach in the biotech sector, striving to change the landscape of vaccine delivery and accessibility.